Abstracts Archive - Page 334 of 1683 - ATC Abstracts

2020 American Transplant Congress
Rates of Live Donor Liver Transplantation Vary by Socioeconomic Status and Geography
D. R. Jorgensen, A. Humar, C. Hughes, M. Molinari, A. Ganoza, S. Ganesh, A. Duarte-Rojo, A. Tevar
Surgery, University of Pittsburgh, Pittsburgh, PA
*Purpose: Live donor liver transplantation (LDT) carries with it many benefits for the recipient, including reduced time on waitlist, transplantation at a lower meld score,…
2020 American Transplant Congress
Hepatocellular Carcinoma Locoregional Therapy: A Comparison of Radiologic Treatment Response and Post-Transplant Pathology
A. J. Hargrove¹, T. Donovan², K. Fisher³, M. Goodenberger⁴, A. Langnas¹, S. Merani¹
¹Department of Surgery, Division of Transplant Surgery, University of Nebraska Medical Center, Omaha, NE, ²Department of Radiology, Division of Interventional Radiology, University of Nebraska Medical Center, Omaha, NE, ³Department of Pathology, University of Nebraska Medical Center, Omaha, NE, ⁴Department of Radiology, Division of Body Imaging, University of Nebraska Medical Center, Omaha, NE
*Purpose: Transplantation or resection is the only potentially curative treatment for Hepatocellular Carcinoma (HCC). Locoregional therapy (LRT) is used exclusively in non-transplant candidates or as…
2020 American Transplant Congress
Taking on Pediatric Liver Tumors – Beyond Hepatoblastoma
U. Ekong, N. Yazigi, K. Khan, S. Kaufman, J. Guerra, R. Girlanda, J. Hawksworth, A. Kroemer, C. Matsumoto, T. Fishbein
MedStar Georgetown Transplant Institute, Washington, DC
*Purpose: Background. Hepatic angiosarcomas, hepatocellular carcinoma, hemangioendothelioma, and rhabdomyosarcoma of the bile ducts are very rare tumors in children with historically poor prognosis. Median survival…
2020 American Transplant Congress
Opioid Prescription Pattern and Risk Factors Associated with Opioid Use after Living Donor Hepatectomy in the US
M. Nguyen¹, L. Vest², Z. Zhang², V. Whittaker³, M. Schnitzler¹, D. Axelrod⁴, H. Randall¹, C. Varma¹, J. Snyder⁵, B. Kasiske⁵, D. Segev⁶, M. McAdams Demarco⁷, G. Hess⁸, K. Lentine²
¹Department of Surgery, Saint Louis University, Saint Louis, MO, ²Department of Medicine, Saint Louis University, Saint Louis, MO, ³Department of Surgery, New York Medical College, New York, NY, ⁴Department of Surgery, University of Iowa, Iowa City, IA, ⁵SRTR, Minneapolis, MN, ⁶Department of Surgery, Johns Hopkins University, Baltimore, MD, ⁷Johns Hopkins University, Baltimore, MD, ⁸Drexel University, Philadelphia, PA
*Purpose: Opioids are the cornerstone of acute pain management after living donor hepatectomy. Their misuse poses the danger of chronic abuse. How this affects living…
2020 American Transplant Congress
Differences in Immunosuppressive Therapy among Liver Retransplantation Recipients in a National Cohort
A. K. Mezochow, P. L. Abt, T. Bittermann
Hospital of the University of Pennsylvania, Philadelphia, PA
*Purpose: There is no unified consensus as to the preferred immunosuppression (IS) strategy following liver retransplantation (reLT). This study explored: (i) factors associated with induction…
2020 American Transplant Congress
Higher Probability of Living Donor Liver Transplantation is Associated with DSAs Having a Higher Median Meld at Transplant
D. Haakinson¹, S. Noreen², D. Stewart², R. Batra¹, G. Gan¹, Y. Deng¹, S. Kulkarni¹
¹Yale, New Haven, CT, ²UNOS, Richmond, VA
*Purpose: Recent studies show that outcomes of living donor liver transplantation (LDLT) are superior compared to those receiving deceased donor grafts. Access to deceased donor…
2020 American Transplant Congress
Predictive Role of the Vitamin B12 in Acute Kidney Injury after Living Donor Liver Transplantation: A Retrospective Observational Cohort Study
J. Park, M. Chae
St.Mary's Hospital, Seoul, Seoul, Korea, Republic of
*Purpose: The aim of our study is to examine the association between serum vitamin B12 level and development of postoperative acute kidney injury (AKI) in…
2020 American Transplant Congress
Is the Survival Impacted by Multiple Cancer after Liver Transplantation? A Retrospective French National Multicentric Study between 1993-2013
M. Altieri
Chu Caen, Caen, France
*Purpose: Introduction: Despite the great progress made in recent decades, post-liver transplant de novo cancers is one of the leading causes of late complications and…
2020 American Transplant Congress
National Experience with Living Donor Liver Transplant for Hepatocellular Carcinoma
J. Silverstein¹, F. Yao¹, J. D. Grab², H. Braun², J. Roberts², J. Dodge², N. Mehta¹
¹Dept of Medicine, UCSF, San Francisco, CA, ²Dept of Surgery, UCSF, San Francisco, CA
*Purpose: LDLT is an attractive option to decrease both wait time and risk of waitlist dropout in HCC. This study aimed to evaluate temporal and…
2020 American Transplant Congress
Risk Factors Associated with Hepatic Artery Thrombosis in the Modern Era
M. Krach, A. Kernodle, P. Chiang, D. Segev, A. Massie, J. Garonzik-Wang
Johns Hopkins, Baltimore, MD
*Purpose: Historically, hepatic artery thrombosis (HAT) has been associated with certain risk factors, such as donor age, cold ischemia time, and split grafts; it is unclear…